Señales en vivo de 603087.SS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 03:00):

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China...

Stats
Volumen de hoy	18.21M
Volumen promedio	12.06M
Capitalización de mercado	29.53B
EPS	CNY0.227 ( 2023-10-30 )
Próxima fecha de ganancias	( CNY0 ) 2024-05-16
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	74.69
ATR14	CNY0.0650 (0.13%)

Volumen Correlación

Largo: -0.50 (neutral)

Corto: 0.50 (neutral)

Signal:(44.062) Neutral

Gan & Lee Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gan & Lee Correlación - Moneda/Commodity

0.21
( neutral )

0.42
( neutral )

0.00
( neutral )

0.17
( neutral )

-0.77
( moderate negative )

-0.19
( neutral )

Gan & Lee Finanzas

Annual	2023
Ingresos:	CNY2.58B
Beneficio Bruto:	CNY1.79B (69.20 %)
EPS:	CNY0.600

FY	2023
Ingresos:	CNY2.58B
Beneficio Bruto:	CNY1.79B (69.20 %)
EPS:	CNY0.600

FY	2022
Ingresos:	CNY1.71B
Beneficio Bruto:	CNY1.31B (76.30 %)
EPS:	CNY-0.780

FY	2021
Ingresos:	CNY3.61B
Beneficio Bruto:	CNY3.22B (89.03 %)
EPS:	CNY2.59

Financial Reports:

No articles found.

Gan & Lee

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.